SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?


To: scaram(o)uche who wrote (8754)6/24/2003 11:19:21 AM
From: Biomaven  Respond to of 52153
 
the DYAX deal with Genzyme (boo!! hiss!!), and the validation of AMEV by Lilly.

I've never really followed DYAX myself, but AMEV is still most interesting at these prices. I'm really just following after RKRW on AMEV, but with still only an $82m market cap, this is one that clearly still has a lot of room to run.

Peter